Literature DB >> 10799879

Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation.

Y Li1, X He, J Schembri-King, S Jakes, J Hayashi.   

Abstract

Lnk was originally cloned from a rat lymph node cDNA library and shown to participate in T cell signaling. Human Lnk (hLnk) was cloned by screening a Jurkat cell cDNA library. hLnk has a calculated molecular mass of 63 kDa, and its deduced amino acid sequence indicates the presence of an N-terminal proline-rich region, a pleckstrin homology domain, and a Src homology 2 domain. When expressed in COS cells, hLnk migrates with an apparent molecular mass of 75 kDa. Confocal fluorescence microscope analysis indicates that in COS cells transfected with an expression vector encoding a chimeric Lnk-green fluorescent protein, hLnk is found at the juxtanuclear compartment and also appears to be localized at the plasma membrane. Lnk is tyrosine-phosphorylated by p56lck. Following phosphorylation, p56lck binds to tyrosine-phosphorylated hLnk through its Src homology 2 domain. In COS cells cotransfected with hLnk, p56lck, and CD8-zeta, hLnk associated with tyrosine-phosphorylated TCR zeta-chain through its Src homology 2 domain. The overexpression of Lnk in Jurkat cells led to an inhibition of anti-CD3 mediated NF-AT-Luc activation. Our study reveals a potentially new mechanism of T cell-negative regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799879     DOI: 10.4049/jimmunol.164.10.5199

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Adaptor protein Lnk inhibits c-Fms-mediated macrophage function.

Authors:  Saskia Gueller; Helen S Goodridge; Birte Niebuhr; Hongtao Xing; Maya Koren-Michowitz; Hubert Serve; David M Underhill; Christian H Brandts; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2010-06-22       Impact factor: 4.962

Review 2.  Detecting shared pathogenesis from the shared genetics of immune-related diseases.

Authors:  Alexandra Zhernakova; Cleo C van Diemen; Cisca Wijmenga
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

Review 3.  Translational mini-review series on the immunogenetics of gut disease: immunogenetics of coeliac disease.

Authors:  P C Dubois; D A van Heel
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

4.  SH2B3: a new leukemia predisposition gene.

Authors:  Cheryl L Willman
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

Review 5.  (2) Classification and diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

6.  LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets α-parvin to control cell adhesion and migration.

Authors:  Julie Devallière; Mathias Chatelais; Juliette Fitau; Nathalie Gérard; Philippe Hulin; Laura Velazquez; Christopher E Turner; Béatrice Charreau
Journal:  FASEB J       Date:  2012-03-21       Impact factor: 5.191

Review 7.  Recent advances in the genetics of systemic lupus erythematosus.

Authors:  Donna L Thibault Flesher; Xin Sun; Timothy W Behrens; Robert R Graham; Lindsey A Criswell
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

8.  Lnk-dependent axis of SCF-cKit signal for osteogenesis in bone fracture healing.

Authors:  Tomoyuki Matsumoto; Masaaki Ii; Hiromi Nishimura; Taro Shoji; Yutaka Mifune; Atsuhiko Kawamoto; Ryosuke Kuroda; Tomoaki Fukui; Yohei Kawakami; Tomoya Kuroda; Sang Mo Kwon; Hiroto Iwasaki; Miki Horii; Ayumi Yokoyama; Akira Oyamada; Sang Yang Lee; Shinya Hayashi; Masahiro Kurosaka; Satoshi Takaki; Takayuki Asahara
Journal:  J Exp Med       Date:  2010-09-20       Impact factor: 14.307

Review 9.  The function of SH2B3 (LNK) in the kidney.

Authors:  Gregory Blass; David L Mattson; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2016-07-20

10.  Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.

Authors:  Igal Louria-Hayon; Catherine Frelin; Julie Ruston; Gerald Gish; Jing Jin; Michael M Kofler; Jean-Philippe Lambert; Hibret A Adissu; Michael Milyavsky; Robert Herrington; Mark D Minden; John E Dick; Anne-Claude Gingras; Norman N Iscove; Tony Pawson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.